Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax®) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip®) to adults aged ≥60 years: An open-label, randomised trial
- Author
- ZIMMERMANN, Ulrich1 ; GAVAZZI, Gaetan2 ; RICHARD, Patrick3 ; EYMIN, Cecile3 ; SOUBEYRAND, Benoît3 ; BAUDIN, Martine3
[1] Internistische Gemeinschaftspraxis, Sülmerstrasse 32, 74072, Heilbronn, Germany
[2] University Hospital of Grenoble, Pavillon Elisé Chatin, BP-217 38043, Grenoble, France
[3] Sanofi Pasteur MSD, 8 rue Jonas Salk, 69367, Lyon, France - Source
Vaccine. 2013, Vol 31, Num 11, pp 1496-1502, 7 p ; ref : 24 ref
- Publisher
- Elsevier, Kidlington
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Author keyword
- Elderly Immune response Inactivated influenza vaccine Randomised controlled trial Safety Tdap-IPV
- Keyword (fr)
- Diphtérie Grippe Immunogénicité Personne âgée Poliomyélite antérieure Rappel vaccination Réponse immune Souche inactivée Tétanos Vaccin acellulaire Bactériose Homme Infection Pathologie de la moelle épinière Pathologie du système nerveux central Pathologie du système nerveux Virose
- Keyword (en)
- Diphtheria Influenza Immunogenicity Elderly Acute anterior poliomyelitis Booster vaccination Immune response Inactivated strain Tetanus Acellular vaccine Bacteriosis Human Infection Spinal cord disease Central nervous system disease Nervous system diseases Viral disease
- Keyword (es)
- Difteria Gripe Inmunogenicidad Anciano Poliomielitis anterior Vacunación de refuerzo Respuesta inmune Cepa inactivada Tetanos Vacuna acelular Bacteriosis Hombre Infección Médula espinal patología Sistema nervosio central patología Sistema nervioso patología Virosis
- Classification
- Pascal
- 002 Biological and medical sciences / 002A Fundamental and applied biological sciences. Psychology / 002A05 Microbiology / 002A05F Applied microbiology / 002A05F04 Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B05 Infectious diseases / 002B05B Bacterial diseases / 002B05B02 Human bacterial diseases / 002B05B02B Ent and stomatologic bacterial diseases
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B05 Infectious diseases / 002B05C Viral diseases / 002B05C02 Human viral diseases / 002B05C02A Viral diseases of the nervous system
- Discipline
- Infectious pathology Microbiology
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 27110629
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1016/j.vaccine.2012.12.081 
https://dx.doi.org/10.1016/j.vaccine.2012.12.081
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/j.vaccine.2012.12.081\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:298:\"Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax\u00ae) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip\u00ae) to adults aged \u226560 years: An open-label, randomised trial\";s:9:\"\u0000*\u0000jtitle\";s:7:\"Vaccine\";s:9:\"\u0000*\u0000stitle\";s:7:\"Vaccine\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"31\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"1496\";s:8:\"\u0000*\u0000epage\";s:4:\"1502\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0264-410X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"ZIMMERMANN\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Ulrich\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:15:\"GAVAZZI, Gaetan\";i:1;s:16:\"RICHARD, Patrick\";i:2;s:13:\"EYMIN, Cecile\";i:3;s:19:\"SOUBEYRAND, Beno\u00eet\";i:4;s:15:\"BAUDIN, Martine\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"VACCDE\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:298:\"Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax\u00ae) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip\u00ae) to adults aged \u226560 years: An open-label, randomised trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/j.vaccine.2012.12.081\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:298:\"Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax\u00ae) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip\u00ae) to adults aged \u226560 years: An open-label, randomised trial\";s:9:\"\u0000*\u0000jtitle\";s:7:\"Vaccine\";s:9:\"\u0000*\u0000stitle\";s:7:\"Vaccine\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"31\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"1496\";s:8:\"\u0000*\u0000epage\";s:4:\"1502\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0264-410X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"ZIMMERMANN\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Ulrich\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:15:\"GAVAZZI, Gaetan\";i:1;s:16:\"RICHARD, Patrick\";i:2;s:13:\"EYMIN, Cecile\";i:3;s:19:\"SOUBEYRAND, Beno\u00eet\";i:4;s:15:\"BAUDIN, Martine\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"VACCDE\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:298:\"Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax\u00ae) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip\u00ae) to adults aged \u226560 years: An open-label, randomised trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/j.vaccine.2012.12.081\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/j.vaccine.2012.12.081\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:298:\"Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax\u00ae) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip\u00ae) to adults aged \u226560 years: An open-label, randomised trial\";s:9:\"\u0000*\u0000jtitle\";s:7:\"Vaccine\";s:9:\"\u0000*\u0000stitle\";s:7:\"Vaccine\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"31\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"1496\";s:8:\"\u0000*\u0000epage\";s:4:\"1502\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0264-410X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"ZIMMERMANN\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Ulrich\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:15:\"GAVAZZI, Gaetan\";i:1;s:16:\"RICHARD, Patrick\";i:2;s:13:\"EYMIN, Cecile\";i:3;s:19:\"SOUBEYRAND, Beno\u00eet\";i:4;s:15:\"BAUDIN, Martine\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"VACCDE\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:298:\"Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax\u00ae) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip\u00ae) to adults aged \u226560 years: An open-label, randomised trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/j.vaccine.2012.12.081\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:298:\"Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax\u00ae) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip\u00ae) to adults aged \u226560 years: An open-label, randomised trial\";s:9:\"\u0000*\u0000jtitle\";s:7:\"Vaccine\";s:9:\"\u0000*\u0000stitle\";s:7:\"Vaccine\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"31\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"1496\";s:8:\"\u0000*\u0000epage\";s:4:\"1502\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0264-410X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"ZIMMERMANN\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Ulrich\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:15:\"GAVAZZI, Gaetan\";i:1;s:16:\"RICHARD, Patrick\";i:2;s:13:\"EYMIN, Cecile\";i:3;s:19:\"SOUBEYRAND, Beno\u00eet\";i:4;s:15:\"BAUDIN, Martine\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"VACCDE\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:298:\"Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax\u00ae) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip\u00ae) to adults aged \u226560 years: An open-label, randomised trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/j.vaccine.2012.12.081\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:298:\"Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax\u00ae) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip\u00ae) to adults aged \u226560 years: An open-label, randomised trial\";s:9:\"\u0000*\u0000jtitle\";s:7:\"Vaccine\";s:9:\"\u0000*\u0000stitle\";s:7:\"Vaccine\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"31\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"1496\";s:8:\"\u0000*\u0000epage\";s:4:\"1502\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0264-410X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"ZIMMERMANN\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Ulrich\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:15:\"GAVAZZI, Gaetan\";i:1;s:16:\"RICHARD, Patrick\";i:2;s:13:\"EYMIN, Cecile\";i:3;s:19:\"SOUBEYRAND, Beno\u00eet\";i:4;s:15:\"BAUDIN, Martine\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"VACCDE\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:298:\"Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax\u00ae) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip\u00ae) to adults aged \u226560 years: An open-label, randomised trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
